전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved22 programs
ADCCurated CoreFDAAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
ADCCurated CoreFDAAbbVieMMAE (microtubule inhibitor)Approved

telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv)

Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression · c-Met

#c-Met#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
AntibodyLimited DatastaleMerck KGaAPhase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 138Status Active
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · HER2

#HER2#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 59Status Recruiting
AntibodyLimited DatastaleXuekui LiuPhase 2

Zimberelimab (Zimberelimab)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable · Prostatic Neoplasms, Castration-Resistan

#ProstaticNeoplasmsCastration-Res#Antibody#Phase2#Popular#monoclonal-antibody+2
Trials 50Status Recruiting
AntibodyLimited DatastaleMridula George, MDPhase 2

Retifanlimab (Retifanlimab)

Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+3
Trials 49Status Recruiting
CGTStandard DatabasestaleLiaoning Medical Diagnosis and …Phase 2

Autologous immune Cells (Autologous immune Cells)

Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) · Lung Cancer (Locally Advanced or Metasta

#LungCancerLocallyAdvancedorMetas#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 31Status Recruiting
AntibodyLimited DatastaleLepu Medical Technology (Beijin…Phase 2

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma · Locally Advanced Oral and Oropharyngeal

#LocallyAdvancedOralandOropharyng#Antibody#Phase2#monoclonal-antibody#Lepu
Trials 11Status Recruiting
ADCLimited DatastaleMing-Yuan ChenPhase 3

Neoadjuvant and Adjuvant Becotatug Vedotin (Neoadjuvant and Adjuvant Becotatug Vedotin)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#ADC#Phase3#antibody-drug-conjugate#Ming-Yuan
Trials 6Status Recruiting
AntibodyLimited DatastaleJanssenPhase 2

Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Locally Recurrent Skin Squamous Cell Car

#LocallyRecurrentSkinSquamousCell#Antibody#Phase2#monoclonal-antibody#MetastaticSkinSquamousCellCarcin+1
Trials 1Status Discontinued
AntibodyLimited DatastaleDong-A ST Co., Ltd.Phase 2

pembrolizumab (Keytruda, DA-4505 + Pembrolizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase2#monoclonal-antibody#Dong-A
Trials 1Status Recruiting
AntibodyLimited DatastaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#monoclonal-antibody#OncoMed
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleHanmi Pharmaceutical Company Li…Phase 1

HM95573, cetuximab (HM95573, cetuximab)

Locally Advanced Solid Tumor; Metastatic Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#MetastaticSolidTumor+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzuamb (Herceptin, Herceptin (trastuzuamb))

HER2 Positive Early or Locally Advanced Breast Cancer · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#HER2PositiveEarlyorLocallyAdvanc+1
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Recruiting
AntibodyLimited DatastaleFirst Affiliated Hospital of We…Phase 2

Serplulimab immunotherapy (Serplulimab immunotherapy)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#monoclonal-antibody#First
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →